All In Biotech

NDA 200656 · Fresenius Kabi USA

Kabiven In Plastic Container

Amino Acids, Calcium Chloride, Dextrose, Magnesium Sulfate, Potassium Chloride, Sodium Acetate, Sodium Glycerophosphate, Soybean Oil · Intravenous · Lipid Emulsion; Amino Acid

Last checked: Nov 19, 2026Latest source record: Jul 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Aug 25, 2014

Approved uses

1

Original approval plus efficacy supplements

Registered trials

30,323

6,603 Phase 3, 2,682 recruiting

FAERS reports

399

394 serious, 75 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 15, 2025.

PERIKABIVEN is indicated as a source of calories, protein, electrolytes and essential fatty acids for adult patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. PERIKABIVEN may be used to prevent essential fatty acid deficiency or treat negative nitrogen balance in adult patients. PERIKABIVEN is indicated as a source of calories, protein, electrolytes and essential fatty acids for adult patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. PERIKABIVEN may be used to prevent essential fatty acid deficiency or treat negative nitrogen balance in adult patients. ( 1 ) Limitations of Use: Not recommended for use in pediatric patients <2 years including preterm infants because the fixed content of the formulation does not meet nutritional requirements in this age group. ( 1 , 5.1 , 8.4 ) Limitations of Use: PERIKABIVEN is not recommended for use in pediatric patients under the age of 2 years, including preterm infants because the fixed content of the formulation does not meet the nutritional requirements of this age group [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.4 )] .

Mechanism: PERIKABIVEN is used as a supplement or as the sole source of nutrition in patients, providing macronutrients (amino acids, dextrose and lipids) and micronutrients (electrolytes) parenterally. The amino acids provide the structural units that make up proteins and are used to synthesize proteins and other biomolecules or are oxidized to urea and carbon dioxide as a source of energy. The administered dextrose is oxidized to carbon dioxide and water, yielding energy. Intravenously administered lipids provide a biologically utilizable source of calories and essential fatty acids. Fatty acids serve...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

7 products under this application
  • KABIVEN IN PLASTIC CONTAINER · AMINO ACIDS 3.3%; CALCIUM CHLORIDE 29MG/100ML; DEXTROSE 9.8GM/100ML; MAGNESIUM SULFATE 96MG/100ML; POTASSIUM CHLORIDE 174MG/100ML; SODIUM ACETATE 239MG/100ML; SODIUM GLYCEROPHOSPHATE 147MG/100ML; SOYBEAN OIL 3.9GM/100ML (2053ML) · EMULSION, INTRAVENOUS · Prescription
  • KABIVEN IN PLASTIC CONTAINER · AMINO ACIDS 3.3%; CALCIUM CHLORIDE 29MG/100ML; DEXTROSE 9.8GM/100ML; MAGNESIUM SULFATE 96MG/100ML; POTASSIUM CHLORIDE 174MG/100ML; SODIUM ACETATE 239MG/100ML ; SODIUM GLYCEROPHOSPHATE 147MG/100ML; SOYBEAN OIL 3.9GM/100ML (1026ML) · EMULSION, INTRAVENOUS · Prescription
  • PERIKABIVEN IN PLASTIC CONTAINER · AMINO ACIDS 2.4%; CALCIUM CHLORIDE 20MG/100ML; DEXTROSE 6.8GM/100ML; MAGNESIUM SULFATE 68MG/100ML; POTASSIUM CHLORIDE 124MG/100ML; SODIUM ACETATE 170MG/100ML; SODIUM GLYCEROPHOSPHATE 105MG/100ML; SOYBEAN OIL 3.5GM/100ML (1920ML) · EMULSION, INTRAVENOUS · Prescription
  • KABIVEN IN PLASTIC CONTAINER · AMINO ACIDS 3.3%; CALCIUM CHLORIDE 29MG/100ML; DEXTROSE 9.8GM/100ML; MAGNESIUM SULFATE 96MG/100ML; POTASSIUM CHLORIDE 174MG/100ML; SODIUM ACETATE 239MG/100ML; SODIUM GLYCEROPHOSPHATE 147MG/100ML; SOYBEAN OIL 3.9GM/100ML (2566ML) · EMULSION, INTRAVENOUS · Prescription
  • KABIVEN IN PLASTIC CONTAINER · AMINO ACIDS 3.3%; CALCIUM CHLORIDE 29MG/100ML; DEXTROSE 9.8GM/100ML; MAGNESIUM SULFATE 96MG/100ML; POTASSIUM CHLORIDE 174MG/100ML; SODIUM ACETATE 239MG/100ML; SODIUM GLYCEROPHOSPHATE 147MG/100ML; SOYBEAN OIL 3.9GM/100ML (1540ML) · EMULSION, INTRAVENOUS · Prescription
  • PERIKABIVEN IN PLASTIC CONTAINER · AMINO ACIDS 2.4%; CALCIUM CHLORIDE 20MG/100ML; DEXTROSE 6.8GM/100ML; MAGNESIUM SULFATE 68MG/100ML; POTASSIUM CHLORIDE 124MG/100ML; SODIUM ACETATE 170MG/100ML ; SODIUM GLYCEROPHOSPHATE 105MG/100ML; SOYBEAN OIL 3.5GM/100ML (2400ML) · EMULSION, INTRAVENOUS · Prescription
  • PERIKABIVEN IN PLASTIC CONTAINER · AMINO ACIDS 2.4%; CALCIUM CHLORIDE 20MG/100ML; DEXTROSE 6.8GM/100ML; MAGNESIUM SULFATE 68MG/100ML; POTASSIUM CHLORIDE 124MG/100ML; SODIUM ACETATE 170MG/100ML; SODIUM GLYCEROPHOSPHATE 105MG/100ML; SOYBEAN OIL 3.5GM/100ML (1440ML) · EMULSION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Amino Acids" as an intervention, any sponsor and status, largest first.

All 30,323 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • chills30
  • pyrexia24
  • nausea22
  • chest discomfort21
  • palpitations20
  • vomiting20
  • death19
  • pneumonia19
  • asthenia18
  • diarrhoea18
  • dyspnoea18
  • foetal growth restriction17

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20065
20076
20088
20096
20107
20119
201235
201312
201410
201511
201623
201724
201815
20199
202011
202114
202216
202379
202457
202528
202613

Recalls

1 FDA enforcement reports for this application.

  • Apr 28, 2015 · Class II · Terminated

    Labeling: Label Error on Declared Strength: Labeled 3.1% Amino Acids but contains 3.3% Amino Acids

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,551 on PubMed

Sponsor: Fresenius Kabi USA · Also marketed as Perikabiven In Plastic Container

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.